MEMANTINE HYDROCHLORIDE | A090043 | UPSHER SMITH LABORATORIES LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Sean Mahoney Upsher-Smith Laboratories Inc FDA-2014-P-1483 · 3 docket documents Upsher-Smith Laboratories, Inc. filed this citizen petition pursuant to sections 505(j) and 505(w) of the Federal Food, Drug, and Cosmetic Act and 21 C.F.R. sections 314.122 and 314.161 requesting that the FDA formally determine that Namenda (memantine hydrochloride) tablets in 5 mg and 10 mg streng | 505(q) | 2014-10-01 | Withdrawn | Sean Mahoney Upsher-Smith Laboratories Inc |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.0800
per ea
Lowest NADAC/Unit
$0.0645
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00832111260MEMANTINE HCL 5 MG TABLET | $0.0800 | EA | Generic | — | 2026-06-17 |
| 00832111360MEMANTINE HCL 10 MG TABLET | $0.0645 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.